Competitive Technologies, Inc. Resolves Litigation With Former Chief Executive Officer

        Print
| Source: Competitive Technologies, Inc.

FAIRFIELD, Conn., Jan. 27, 2012 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) today announced that it has settled all disputes with its former Chairman and CEO John B. Nano. Mr. Nano filed an arbitration demand against CTTC in September 2010 claiming that he was entitled to employment severance payments, while CTTC defended on the basis of its position that Mr. Nano was terminated for cause. By decisions in August and September 2011, the arbitrator awarded Mr. Nano the full amount of his claim, and in recent days the Superior Court of Connecticut confirmed the arbitration award to Mr. Nano.

Pursuant to the settlement, CTTC has released to Mr. Nano from escrow the $750,000 deposited by CTTC following Mr. Nano's application for a prejudgment remedy. CTTC will pay an additional $25,000 as settlement of additional amounts of statutory interest. The settlement includes mutual general releases of any and all claims either party has or had against the other. The settlement agreement also includes a provision that neither CTTC nor Mr. Nano would disparage the other. Should any such disparagement occur and litigation ensue, they further agreed that the prevailing party would be entitled to recover its costs and expenses, including reasonable attorney's fees. CTTC's payments to Mr. Nano will be completed by January 30, 2012.

About Competitive Technologies, Inc.

Competitive Technologies is a global leader in developing and commercializing innovative products and technologies. CTTC is multifaceted, providing distribution, patent and technology transfer, sales and licensing services. CTTC's staff is focused on the needs of customers and matching those requirements with commercially viable products or technology solutions.

CTTC is the licensed worldwide distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy™" technology developed in Italy by CTTC's client, Professor Giuseppe Marineo, to treat neuropathic pain, including cancer pain. The Calmare® device is currently being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of Seoul, Korea. For more information on the device, visit www.calmarett.com. Visit CTTC's website: www.competitivetech.net.

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2010, filed with the SEC on October 27, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Jean Wilczynski
IR Services, LLC
(860.434.2465/)